NCT05356741
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05356741
Title To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Vir Biotechnology, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries FRA | ESP | AUS


No variant requirements are available.